Clinical Trial Update: T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating the combination of T-DM1 (ado-trastuzumab emtansine) and pertuzumab as neoadjuvant therapy for early-stage HER2-positive breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)
• Perjeta (pertuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: HER-2 Positive Breast Cancer, Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-05-11